Regulatory review company Advarra surpassed a milestone by expanding its gene therapy network to more than 1,000 research sites.
The mark helps cement Advarra’s claim to be the largest global administrator of institutional biosafety committees (IBCs), the company said in an Oct. 11 press release. These sites use the Advarra Gene Therapy Ready platform, which launched in 2021, and include facilities that conduct clinical trials involving genetically engineered vaccines, gene-modified cellular therapies and gene therapies.
“In a very short time, we have demonstrated the value Advarra’s integrated research services bring to the research community, as they develop advanced cell and gene therapies to find cures for the world’s most pressing health conditions,” Scott Uebele, Advarra’s president and chief research services officer, said in the release.
Advarra’s aim is to bring life sciences companies, CROs, research sites, investigators and academia together. The company’s network saw explosive growth during the COVID-19 pandemic as it supported all of the vaccine clinical trials covered by the U.S. government’s Warp Speed program. Advarra’s technology helped shrink IBC research approval times for the vaccine trials to less than two working days.